Alnylam Pharmaceuticals (ALNY) said late Thursday that the US Food and Drug Administration has approved the supplemental new drug application for its drug Amvuttra for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
The approval of the drug, also known as vutrisiran, is meant to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits, the company said.
ATTR-CM is a rapidly progressive and ultimately heart disease without a cure.
The approval is based on a phase 3 clinical trial in which Amvuttra showed statistically significant improvement compared with a placebo in all of its 10 pre-specified primary and secondary endpoints, reducing mortality by 36% over 42 months, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.